Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PRKCA | P17252 | 4/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11000682 | 1.00 | KDM4E (0.36) | KDM4EALDH1A1GAAHPGDSMN1; SMN2 | |
| SCHEMBL2186874 | 1.00 | KDM4E (0.36) | KDM4EALDH1A1GAAHPGDSMN1; SMN2 | |
| SCHEMBL21408682 | 0.83 | CYP1A2 (0.41) | HPGDPOLBPRKCASIRT2 | |
| SCHEMBL21408496 | 0.82 | CYP1A2 (0.47) | PRKCASIRT2 | |
| SCHEMBL21408663 | 0.80 | CYP1A2 (0.46) | PRKCASIRT2 | |
| SCHEMBL18642656 | 0.80 | LMNA (0.33) | LMNATSHRSIRT2 | |
| SCHEMBL21314187 | 0.80 | LMNA (0.33) | LMNATSHRSIRT2 | |
| SCHEMBL1357905 | 0.79 | CA1 (0.35) | ALDH1A1GAAHPGDSMN1; SMN2LMNA | |
| SCHEMBL3795302 | 0.79 | CA1 (0.35) | ALDH1A1GAAHPGDSMN1; SMN2LMNA | |
| SCHEMBL10988832 | 0.79 | CA1 (0.35) | ALDH1A1GAAHPGDSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4519944-A | Spirolactones as odorants | GIVAUDAN CORPORATION (US) | 1985-05-28 | — | — | US | claimed |
| EP-1742929-B1 | Trisubstituted furans suitable for the preparation of fragrance compositions | GIVAUDAN SA (CH) | 2012-06-20 | — | — | EP | disclosed |
| US-7632790-B2 | 2,2-Disubstituted-5-methyl-2,5-dihydro- and 2,2-disubstituted 5-methyl-tetrahydrofurans; 2-tert-butyl-5-methyl-2-propyl-2,5-dihydrofuran or tetrahydrofuran;black currant odorants free of any sulfur by-products; fruity; impart naturalness andfreshness; cosmetics; toiletries; laundering | GIVAUDAN S.A. (CH) | 2009-12-15 | — | — | US | disclosed |
| US-20080039360-A1 | Trisubstituted Furans Suitable For The Preparation Of Fragrance Compositions | GIVAUDAN S.A. (CH) | 2008-02-14 | — | — | US | disclosed |
| EP-1742929-A1 | TRISUBSTITUTED FURANS SUITABLE FOR THE PREPARATION OF FRAGRANCE COMPOSITIONS | Givaudan SA (CH) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005087756-A1 | TRISUBSTITUTED FURANS SUITABLE FOR THE PREPARATION OF FRAGRANCE COMPOSITIONS | GIVAUDAN SA (CH) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039360-A1 | Trisubstituted Furans Suitable For The Preparation Of Fragrance Compositions | TAS2R5, TAS2R1, DHPS | KDM4E 437/4885ALDH1A1 163/4885GAA 4783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.